https://www.selleckchem.com/products/GDC-0449.html
High levels of CA19-9 and not satisfying the Yonsei criteria were significantly associated with a high Foxp3⁺/CD8⁺ ratio [Exp(β)=3.558; 95% confidence inverval 1.000-12.658; p=0.050]. CONCLUSION Yonsei criteria may be clinically detectable biologic marker with which to predict immunologic status and survival in pancreatic cancer patients. © Copyright Yonsei University College of Medicine 2020.PURPOSE We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improve clinical outcomes without affecting safety.
Aimer
Commentaire
Partagez
